erlotinib hydrochloride has been researched along with thromboxane b2 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (thromboxane b2) | Trials (thromboxane b2) | Recent Studies (post-2010) (thromboxane b2) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 7,483 | 715 | 485 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanayama, K; Hirashima, T; Imamura, F; Kanazawa, S; Kinoshita, Y; Nomura, S; Sasada, S; Siomi, K; Tujimoto, M; Yamaguchi, K | 1 |
1 other study(ies) available for erlotinib hydrochloride and thromboxane b2
| Article | Year |
|---|---|
Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Platelet Activation; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Quinazolines; Thromboxane B2; Treatment Outcome | 2009 |